Drugs /

rigosertib

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. Polo-like kinase 1 inhibitor ON 01910.Na inhibits polo-like kinase1 (Plk1), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.

Clinical Trials

View Clinical Trials for rigosertib

Rigosertib has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating rigosertib, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open).

Complex karyotype, EGFR A763_Y764insFQEA, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for rigosertib clinical trials.

Lung adenocarcinoma, myelodysplastic syndromes, and refractory anemia with excess blasts are the most common diseases being investigated in rigosertib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rigosertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rigosertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
syb l-1101, estybon, on 01910.na, polo-like kinase 1 inhibitor on 01910.na, rigosertib sodium, rigosertib sodium, pi-3 kinase inhibitor on 01910.na, polo-like kinase 1 inhibitor on 01919.na, on01910, on 01910
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
PLK1
NCIT ID [1]:
C152216

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.